TACOMA, Wash., March 22 /PRNewswire/ -- Northwest Kinetics Inc. in Tacoma, Wash. has entered into a pivotal phase I clinical trial with DVC LLC, a CSC company, for evaluation of the Venezuelan equine encephalitis (VEE) vaccine candidate V3526. VEE is a mosquito-transmitted viral disease that causes encephalitis in horses and humans. It is an important public health problem in Central and South America. The trial will evaluate the safety, tolerability and immunogenicity of the vaccine candidate in healthy volunteers between the ages of 18 and 40. Clinical testing is underway at Northwest Kinetics and will continue into 2006. This work is being conducted under contract for the Department of Defense Joint Vaccine Acquisition Program (JVAP).
(Logo: http://www.newscom.com/cgi-bin/prnh/20060214/NKLOGO )
About Northwest Kinetics
Northwest Kinetics' vision is to be the premier early phase clinical research partner for pharmaceutical and biotechnology companies. Located in a brand new, built-to-suit facility with 148 beds in Tacoma Washington, we offer single-study capacity, advanced technical capability, and a full range of services for both short- and long-term Phase 0, I and II clinical studies of investigational drugs, vaccines, and devices. The facility's state-of-the-art design amplifies the company's strength in conducting complex and procedure- intensive trials. Sponsors' monitors enjoy private rooms, communications and business equipment support, and convenient access to the Clinical Investigators, Project Managers and other study personnel. Founded in 1995, we are the industry leader in the western United States. For more information, please visit www.nwkinetics.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20060214/NKLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comNorthwest Kinetics Inc.CONTACT: Colleen Hoke, Director of Business Operations of NorthwestKinetics Inc., +1-253-593-5304
Web site: http://www.nwkinetics.com/
